Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma

<div>Molecular characteristics of different risk groups. (a) GO enrichment in TCGA database. (b) KEGG pathways in TCGA database. (c) GSEA in the high-risk group. (d) GSEA in the low-risk group. (e) The mutated genes (top 10) in different risk groups.</div>

Genetics Research

fig8

Figure 8

Figure 8: Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma 

Figure 8 | Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma 